Source: European Medicines Agency (EU) Revision Year: 2023 Publisher: Takeda Pharma A/S, Delta Park 45, 2665 Vallensbaek Strand, Denmark medinfoEMEA@takeda.com
Vipidia 6.25 mg film-coated tablets.
Vipidia 12.5 mg film-coated tablets.
Vipidia 25 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Vipidia 6.25 mg film-coated tablets: Light pink, oval (approximately 9.1 mm long by 5.1 mm wide), biconvex, film-coated tablets with “TAK” and “ALG-6.25” printed in grey ink on one side. Vipidia 12.5 mg film-coated tablets: Yellow, oval (approximately 9.1 mm long by 5.1 mm wide), biconvex, film-coated tablets with “TAK” and “ALG-12.5” printed in grey ink on one side. Vipidia 25 mg film-coated tablets: Light red, oval (approximately 9.1 mm long by 5.1 mm wide), biconvex, film-coated tablets with “TAK” and “ALG-25” printed in grey ink on one side. |
Vipidia 6.25 mg film-coated tablets: Each tablet contains alogliptin benzoate equivalent to 6.25 mg alogliptin.
Vipidia 12.5 mg film-coated tablets: Each tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin.
Vipidia 25 mg film-coated tablets: Each tablet contains alogliptin benzoate equivalent to 25 mg alogliptin.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Alogliptin |
Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high. |
| List of Excipients |
|---|
|
Tablet core: Mannitol Film-coating: Hypromellose Printing ink: Shellac |
Polychlorotrifluoroethylene (PCTFE)/polyvinyl chloride (PVC) blisters with push through aluminium lidding foil. Pack sizes of 10, 14, 28, 30, 56, 60, 84, 90, 98 or 100 film-coated tablets.
Not all pack sizes may be marketed.
Takeda Pharma A/S, Delta Park 45, 2665 Vallensbaek Strand, Denmark
medinfoEMEA@takeda.com
EU/1/13/844/001-030
Date of first authorisation: 19 September 2013
Date of latest renewal: 24 May 2018
| Drug | Countries | |
|---|---|---|
| VIPIDIA | Austria, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Poland, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
